Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Diversified Healthcare Trust Leads These 3 Undervalued Small Caps With Insider Activity In US

In This Article:

The United States market has shown robust performance, climbing by 2.8% over the past week and up 25% over the last 12 months, with earnings projected to grow by 15% annually in the coming years. In this context, identifying stocks that are potentially undervalued and exhibit insider activity can be a strategic approach for investors seeking opportunities amidst these favorable conditions.

Top 10 Undervalued Small Caps With Insider Buying In The United States

Name

PE

PS

Discount to Fair Value

Value Rating

OptimizeRx

NA

1.1x

46.05%

★★★★★☆

Quanex Building Products

35.9x

0.9x

35.94%

★★★★☆☆

Franklin Financial Services

9.6x

1.9x

40.25%

★★★★☆☆

McEwen Mining

4.1x

2.1x

46.42%

★★★★☆☆

ProPetro Holding

NA

0.6x

39.21%

★★★★☆☆

German American Bancorp

14.9x

4.9x

45.15%

★★★☆☆☆

First United

13.6x

3.1x

47.40%

★★★☆☆☆

Community West Bancshares

18.7x

2.9x

42.25%

★★★☆☆☆

Delek US Holdings

NA

0.1x

-61.98%

★★★☆☆☆

Sabre

NA

0.5x

-81.96%

★★★☆☆☆

Click here to see the full list of 45 stocks from our Undervalued US Small Caps With Insider Buying screener.

We'll examine a selection from our screener results.

Diversified Healthcare Trust

Simply Wall St Value Rating: ★★★☆☆☆

Overview: Diversified Healthcare Trust operates a portfolio focused on medical office, life science properties, and senior housing facilities with a market capitalization of $1.22 billion.

Operations: The company generates revenue primarily from its Senior Housing Operating Portfolio (SHOP), followed by its Medical Office and Life Science Portfolio. Over recent periods, the gross profit margin showed a trend of fluctuation, reaching 16.87% in the latest quarter. The cost of goods sold (COGS) constitutes a significant portion of expenses, impacting overall profitability.

PE: -1.4x

Diversified Healthcare Trust, a small company in the healthcare sector, has faced financial challenges with a net loss of US$98.69 million for Q3 2024, widening from US$65.78 million the previous year. Despite sales dipping slightly to US$61.64 million this quarter from last year's US$63.39 million, revenue grew to US$373.64 million from US$356.52 million annually due to increased operational activities. While debt coverage by operating cash flow is weak and funding relies solely on external borrowing, insider confidence was evidenced by recent share purchases within the past year, signaling potential optimism about future performance amidst current fiscal constraints and dividend affirmations of $0.01 per share quarterly suggest continued shareholder engagement despite losses.